Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 3/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 8/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.32 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.32 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8931481 | 0.86 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1TUBB4ATUBBTUBA3C | |
| SCHEMBL14328376 | 0.83 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL419166 | 0.79 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL12203091 | 0.76 | TUBB4A (0.36) | OXTRHSP90AA1HSP90AB1TUBB4ATUBB | |
| SCHEMBL4566153 | 0.74 | CACNA1H (0.32) | CACNA1HHSP90AA1HSP90AB1GAA | |
| SCHEMBL12486604 | 0.72 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 | |
| SCHEMBL13060042 | 0.69 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL421461 | 0.69 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1 | |
| SCHEMBL15759985 | 0.68 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL421467 | 0.68 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9090569-B2 | Triazone compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-8993608-B2 | Method for inhibiting topoisomerase II | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8969396-B2 | Method for treating a B-raf associated cancer with an Hsp90 inhibitor | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140221375-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140141511-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8648104-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110009397-A1 | TRIAZONE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-01-13 | — | — | US | disclosed |
| US-20100280032-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7825148-B2 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP | 2010-04-15 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221375-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | OXTR 4601/4885CACNA1H 4786/4885HSP90AA1 3/4885 |
| US-20100280032-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | OXTR 2856/4885CACNA1H 4342/4885HSP90AA1 531/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | OXTR 4767/4885CACNA1H 4866/4885HSP90AA1 3/4885 |
| US-20100093717-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | OXTR 3370/4885CACNA1H 4845/4885HSP90AA1 2/4885 |
| US-20110009397-A1 | TRIAZONE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AB2P, HSP90AA1 | OXTR 4822/4885CACNA1H 4825/4885HSP90AA1 3/4885 |
| US-20140141511-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | OXTR 2856/4885CACNA1H 4342/4885HSP90AA1 531/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | OXTR 4776/4885CACNA1H 4637/4885HSP90AA1 4/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | OXTR 4777/4885CACNA1H 4437/4885HSP90AA1 8/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | OXTR 2856/4885CACNA1H 4342/4885HSP90AA1 531/4885 |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | HSP90AB1, HSP90B1, HSP90AA1 | OXTR 4622/4885CACNA1H 4663/4885HSP90AA1 3/4885 |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | OXTR 4601/4885CACNA1H 4786/4885HSP90AA1 3/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | OXTR 4767/4885CACNA1H 4866/4885HSP90AA1 3/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | OXTR 4854/4885CACNA1H 4858/4885HSP90AA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.